Previous PostPoseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
Next PostAsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer